The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome

Thozhukat Sathyapalan, Anne Marie Coady, Eric S. Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

Abstract

Background: There is an increased risk of developing T2DM in women with polycystic ovary syndrome (PCOS), and there is evidence that statins improve metabolic parameters in these patients. However, there are some data to show that statins increase the risk of incipient diabetes. Materials and methods: We have previously shown that 12 weeks of atorvastatin improves insulin resistance when measured using HOMA-IR. This post hoc analysis was designed to look at the effect of atorvastatin on pancreatic β cell function using HOMA-β in the same study. In this randomised, double-blind placebo controlled study, 40 medication-naïve patients with PCOS were randomised to either atorvastatin 20 mg daily or placebo for 3 months. A 3-month extension study for both groups of patients was undertaken with metformin 1500 mg daily after completing initial 3 months of atorvastatin or placebo. Results: There was a significant reduction in HOMA-β (240 ± 3.2 vs 177 ± 2.3; P value <0.01) after 12 weeks of atorvastatin treatment, which was maintained by metformin in the subsequent 12 weeks. There were no changes in HOMA-β after the placebo or after subsequent metformin treatment. There was no linear correlation between reduction in HOMA-β with improvement of free androgen index (FAI) (r2= 0.02; P = 0.72), testosterone (r2= 0.13; P = 0.49), SHBG (r2= 0.22; P = 0.48), hsCRP (r2= 0.19; P = 0.64), triglycerides (r2= 0.09; P = 0.12), total cholesterol (r2= 0.11; P = 0.32) or LDL-C (r2= 0.19; P = 0.38). Conclusion: Treatment with atorvastatin for 12 weeks in women with PCOS significantly reduced HOMA-β. This could be potentially due to fall in β-cell requirement with improvement of insulin resistance rather than a reduction of β-cell function.

Original languageEnglish
Pages (from-to)811-816
Number of pages6
JournalEndocrine Connections
Volume6
Issue number8
DOIs
Publication statusPublished - 1 Nov 2017

Fingerprint

Polycystic Ovary Syndrome
Insulin-Secreting Cells
Metformin
Placebos
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Insulin Resistance
Androgens
Testosterone
Atorvastatin Calcium
Triglycerides
Therapeutics
Cholesterol

Keywords

  • Insulin resistance
  • Polycystic ovary syndrome
  • Statin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. / Sathyapalan, Thozhukat; Coady, Anne Marie; Kilpatrick, Eric S.; Atkin, Stephen.

In: Endocrine Connections, Vol. 6, No. 8, 01.11.2017, p. 811-816.

Research output: Contribution to journalArticle

Sathyapalan, Thozhukat ; Coady, Anne Marie ; Kilpatrick, Eric S. ; Atkin, Stephen. / The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. In: Endocrine Connections. 2017 ; Vol. 6, No. 8. pp. 811-816.
@article{47b366f5294a4841b71e6de41b24d200,
title = "The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome",
abstract = "Background: There is an increased risk of developing T2DM in women with polycystic ovary syndrome (PCOS), and there is evidence that statins improve metabolic parameters in these patients. However, there are some data to show that statins increase the risk of incipient diabetes. Materials and methods: We have previously shown that 12 weeks of atorvastatin improves insulin resistance when measured using HOMA-IR. This post hoc analysis was designed to look at the effect of atorvastatin on pancreatic β cell function using HOMA-β in the same study. In this randomised, double-blind placebo controlled study, 40 medication-na{\"i}ve patients with PCOS were randomised to either atorvastatin 20 mg daily or placebo for 3 months. A 3-month extension study for both groups of patients was undertaken with metformin 1500 mg daily after completing initial 3 months of atorvastatin or placebo. Results: There was a significant reduction in HOMA-β (240 ± 3.2 vs 177 ± 2.3; P value <0.01) after 12 weeks of atorvastatin treatment, which was maintained by metformin in the subsequent 12 weeks. There were no changes in HOMA-β after the placebo or after subsequent metformin treatment. There was no linear correlation between reduction in HOMA-β with improvement of free androgen index (FAI) (r2= 0.02; P = 0.72), testosterone (r2= 0.13; P = 0.49), SHBG (r2= 0.22; P = 0.48), hsCRP (r2= 0.19; P = 0.64), triglycerides (r2= 0.09; P = 0.12), total cholesterol (r2= 0.11; P = 0.32) or LDL-C (r2= 0.19; P = 0.38). Conclusion: Treatment with atorvastatin for 12 weeks in women with PCOS significantly reduced HOMA-β. This could be potentially due to fall in β-cell requirement with improvement of insulin resistance rather than a reduction of β-cell function.",
keywords = "Insulin resistance, Polycystic ovary syndrome, Statin, Type 2 diabetes",
author = "Thozhukat Sathyapalan and Coady, {Anne Marie} and Kilpatrick, {Eric S.} and Stephen Atkin",
year = "2017",
month = "11",
day = "1",
doi = "10.1530/EC-17-0217",
language = "English",
volume = "6",
pages = "811--816",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",
number = "8",

}

TY - JOUR

T1 - The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome

AU - Sathyapalan, Thozhukat

AU - Coady, Anne Marie

AU - Kilpatrick, Eric S.

AU - Atkin, Stephen

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: There is an increased risk of developing T2DM in women with polycystic ovary syndrome (PCOS), and there is evidence that statins improve metabolic parameters in these patients. However, there are some data to show that statins increase the risk of incipient diabetes. Materials and methods: We have previously shown that 12 weeks of atorvastatin improves insulin resistance when measured using HOMA-IR. This post hoc analysis was designed to look at the effect of atorvastatin on pancreatic β cell function using HOMA-β in the same study. In this randomised, double-blind placebo controlled study, 40 medication-naïve patients with PCOS were randomised to either atorvastatin 20 mg daily or placebo for 3 months. A 3-month extension study for both groups of patients was undertaken with metformin 1500 mg daily after completing initial 3 months of atorvastatin or placebo. Results: There was a significant reduction in HOMA-β (240 ± 3.2 vs 177 ± 2.3; P value <0.01) after 12 weeks of atorvastatin treatment, which was maintained by metformin in the subsequent 12 weeks. There were no changes in HOMA-β after the placebo or after subsequent metformin treatment. There was no linear correlation between reduction in HOMA-β with improvement of free androgen index (FAI) (r2= 0.02; P = 0.72), testosterone (r2= 0.13; P = 0.49), SHBG (r2= 0.22; P = 0.48), hsCRP (r2= 0.19; P = 0.64), triglycerides (r2= 0.09; P = 0.12), total cholesterol (r2= 0.11; P = 0.32) or LDL-C (r2= 0.19; P = 0.38). Conclusion: Treatment with atorvastatin for 12 weeks in women with PCOS significantly reduced HOMA-β. This could be potentially due to fall in β-cell requirement with improvement of insulin resistance rather than a reduction of β-cell function.

AB - Background: There is an increased risk of developing T2DM in women with polycystic ovary syndrome (PCOS), and there is evidence that statins improve metabolic parameters in these patients. However, there are some data to show that statins increase the risk of incipient diabetes. Materials and methods: We have previously shown that 12 weeks of atorvastatin improves insulin resistance when measured using HOMA-IR. This post hoc analysis was designed to look at the effect of atorvastatin on pancreatic β cell function using HOMA-β in the same study. In this randomised, double-blind placebo controlled study, 40 medication-naïve patients with PCOS were randomised to either atorvastatin 20 mg daily or placebo for 3 months. A 3-month extension study for both groups of patients was undertaken with metformin 1500 mg daily after completing initial 3 months of atorvastatin or placebo. Results: There was a significant reduction in HOMA-β (240 ± 3.2 vs 177 ± 2.3; P value <0.01) after 12 weeks of atorvastatin treatment, which was maintained by metformin in the subsequent 12 weeks. There were no changes in HOMA-β after the placebo or after subsequent metformin treatment. There was no linear correlation between reduction in HOMA-β with improvement of free androgen index (FAI) (r2= 0.02; P = 0.72), testosterone (r2= 0.13; P = 0.49), SHBG (r2= 0.22; P = 0.48), hsCRP (r2= 0.19; P = 0.64), triglycerides (r2= 0.09; P = 0.12), total cholesterol (r2= 0.11; P = 0.32) or LDL-C (r2= 0.19; P = 0.38). Conclusion: Treatment with atorvastatin for 12 weeks in women with PCOS significantly reduced HOMA-β. This could be potentially due to fall in β-cell requirement with improvement of insulin resistance rather than a reduction of β-cell function.

KW - Insulin resistance

KW - Polycystic ovary syndrome

KW - Statin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85034610089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034610089&partnerID=8YFLogxK

U2 - 10.1530/EC-17-0217

DO - 10.1530/EC-17-0217

M3 - Article

VL - 6

SP - 811

EP - 816

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 8

ER -